Biocon's Pertuzumab Biosimilar Gets EU Marketing Authorization
Biocon's biosimilar pertuzumab, Pebrilzo®, received marketing authorization from the European Commission for HER2-positive breast cancer treatment. This is the first biosimilar approved under EMA's new tailored clinical approach. It follows a positive CHMP opinion on September 17, 2026. This approval strengthens Biocon's global oncology portfolio.
Receiving marketing authorization in the EU for a key oncology biosimilar is a major regulatory and commercial achievement that will significantly impact Biocon's revenue and market presence in the European region.
The European Commission's marketing authorization for Biocon's biosimilar pertuzumab is a significant positive development, expanding access to a crucial cancer treatment and strengthening the company's global market position.
Biocon Limited announced that the European Commission (EC) has granted marketing authorization for its biosimilar pertuzumab, Pebrilzo®, for the treatment of HER2-positive breast cancer in the European Union. This approval marks the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach, following a positive CHMP opinion on September 17, 2026.
Shreehas Tambe, CEO & Managing Director of Biocon, stated that this approval is a significant regulatory milestone, making pertuzumab Biocon's fifth oncology biosimilar approved in both Europe and the United States. This strengthens the company's global oncology portfolio and its commitment to providing affordable biologic therapies.
The biosimilar pertuzumab is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant and adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. It is also indicated for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.
Biocon highlighted that extensive analytical characterization and clinical data demonstrated its pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy. The company has a strong commitment to oncology, with a growing portfolio and a focus on addressing unmet needs across various stages of cancer care.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.